Finance

Lists
LBRX:NASDAQ
LB Pharmaceuticals Inc
$34.90
+1.87%
(+0.64) 1D
Oct 7, 1:12:35 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LBRX...
Open
$34.02
High
$36.57
Low
$34.02
Mkt. cap
1.13B
Avg. vol.
339.63K
Volume
234.56K
52-wk high
$50.16
52-wk low
$14.32
EPS
-$2.98
Shares outstanding
32.26M
No. of employees
49
Open
$34.02
High
$36.57
Low
$34.02
Mkt. cap
1.13B
Avg. vol.
339.63K
Volume
234.56K
52-wk high
$50.16
52-wk low
$14.32
EPS
-$2.98
Shares outstanding
32.26M
No. of employees
49
News stories
From web sources and news partners
About LB Pharmaceuticals Inc
CEO-
Employees49
Founded2015
Headquarters-
SectorPharmaceutical industry
Analyst ratings
Based on 9 analysts giving stock ratings to LBRX in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for LBRX in the last 3 months.
Highest
Current $34.90
$80.00 (+129.23%)
Average
$59.33 (+70.00%)
Lowest
$35.00 (+0.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yatin Suneja
Guggenheim
Buy
Initiated
$80.00
+129.2%
10/05/2026
Unknown Analyst
Guggenheim
Buy
Initiated
$80.00
+129.2%
10/05/2026
Boobalan Pachaiyappan
Roth MKM
Hold
Downgraded
$35.00
+0.3%
10/05/2026
Ami Fadia
Needham
Buy
Initiated
$68.00
+94.8%
10/02/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$60.00
+71.9%
08/24/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
$69.00
+97.7%
08/21/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$53.00
+51.9%
08/13/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
$45.00
+28.9%
08/12/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$78.00
+123.5%
08/03/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$46.00
+31.8%
07/21/2026
Malcolm Hoffman
BMO Capital
Buy
Initiated
$46.00
+31.8%
07/21/2026
Rudy Li
Wolfe Research
Buy
Initiated
$45.00
+28.9%
07/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2.42M
7.98M
14.54M
43.05M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.83M
4.99M
7.46M
8.97M
Operating expense
5.25M
12.97M
22.00M
52.02M
Total operating expenses
5.25M
12.97M
22.00M
52.02M
Operating income
-5.25M
-12.97M
-22.00M
-52.02M
Other non operating income
983.00K
-401.00K
200.00K
-662.00K
EBT including unusual items
-3.56M
-11.47M
-19.05M
-51.60M
EBT excluding unusual items
-3.56M
-10.57M
-18.95M
-49.70M
Income tax expense
-
1.00K
-
-
Effective tax rate
-
-0.01%
-
-
Other operating expenses
-
-
-
-
Net income
-3.56M
-11.47M
-19.05M
-51.60M
Net profit margin
-
-
-
-
Earnings per share
-0.61
-0.45
-0.67
-1.71
Interest and investment income
707.00K
2.80M
2.85M
2.97M
Interest expense
-
-
-
-
Net interest expenses
707.00K
2.80M
2.85M
2.97M
Depreciation and amortization charges
-
-
-
-
EBITDA
-5.16M
-12.88M
-21.92M
-51.92M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps